| __timestamp | Arrowhead Pharmaceuticals, Inc. | Xencor, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 24419536 | 7461000 |
| Thursday, January 1, 2015 | 34718089 | 11960000 |
| Friday, January 1, 2016 | 40998209 | 13108000 |
| Sunday, January 1, 2017 | 32022880 | 17501000 |
| Monday, January 1, 2018 | 19110051 | 22472000 |
| Tuesday, January 1, 2019 | 26556257 | 24286000 |
| Wednesday, January 1, 2020 | 52275890 | 29689000 |
| Friday, January 1, 2021 | 80981000 | 38837000 |
| Saturday, January 1, 2022 | 124431000 | 47489000 |
| Sunday, January 1, 2023 | 90932000 | 53379000 |
| Monday, January 1, 2024 | 98761000 |
Infusing magic into the data realm
In the competitive world of biotechnology, operational efficiency is key. Arrowhead Pharmaceuticals, Inc. and Xencor, Inc. have been at the forefront of innovation, but how do their operational costs compare? From 2014 to 2023, Arrowhead's Selling, General, and Administrative (SG&A) expenses surged by over 300%, peaking in 2022. This reflects their aggressive expansion and investment in research. In contrast, Xencor's SG&A expenses grew steadily, doubling over the same period, indicating a more conservative growth strategy. Notably, Arrowhead's expenses in 2023 were nearly 70% higher than Xencor's, highlighting their differing approaches. However, data for 2024 is incomplete, leaving room for speculation on future trends. This analysis provides a window into the strategic priorities of these biotech leaders, offering valuable insights for investors and industry watchers alike.
Comparing SG&A Expenses: Merck & Co., Inc. vs Xencor, Inc. Trends and Insights
Comparing SG&A Expenses: Genmab A/S vs Arrowhead Pharmaceuticals, Inc. Trends and Insights
Operational Costs Compared: SG&A Analysis of Halozyme Therapeutics, Inc. and Arrowhead Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: Ionis Pharmaceuticals, Inc. vs Xencor, Inc.
Comparing SG&A Expenses: Alkermes plc vs Arrowhead Pharmaceuticals, Inc. Trends and Insights
Breaking Down SG&A Expenses: Ultragenyx Pharmaceutical Inc. vs Arrowhead Pharmaceuticals, Inc.
Comparing SG&A Expenses: Catalyst Pharmaceuticals, Inc. vs Xencor, Inc. Trends and Insights
Operational Costs Compared: SG&A Analysis of Arrowhead Pharmaceuticals, Inc. and Mesoblast Limited
Arrowhead Pharmaceuticals, Inc. and Geron Corporation: SG&A Spending Patterns Compared
Arrowhead Pharmaceuticals, Inc. vs Celldex Therapeutics, Inc.: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for Arrowhead Pharmaceuticals, Inc. and Evotec SE
Who Optimizes SG&A Costs Better? Ligand Pharmaceuticals Incorporated or Xencor, Inc.